Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development
- PMID: 17503894
- DOI: 10.2165/00002512-200724050-00002
Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development
Abstract
Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists and antagonists. These drugs have been intensively studied over the past decade and have proven to be a highly versatile group for the treatment of different conditions associated with aging, including hormone-responsive cancer and osteoporosis. Tamoxifen and toremifene are currently used to treat advanced breast cancer and also have beneficial effects on bone mineral density and serum lipids in postmenopausal women. Raloxifene is the only SERM approved worldwide for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures. However, although these SERMs have many benefits, they may also be responsible for some potentially very serious adverse effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer. These adverse effects represent a major concern given that long-term therapy is required to prevent osteoporosis. Moreover, both preclinical and clinical reports suggest that tamoxifen, toremifene and raloxifene are considerably less potent than estrogen. The search for the 'ideal' SERM, which would have estrogenic effects on bone and serum lipids, neutral effects on the uterus, and antiestrogenic effects on breast tissue, but none of the adverse effects associated with current therapies, is currently under way. Ospemifene, lasofoxifene, bazedoxifene and arzoxifene, which are new SERM molecules with potential greater efficacy and potency than previous SERMs, are currently under investigation for use in the treatment and prevention of osteoporosis. These drugs have been shown to be comparably effective to conventional hormone replacement therapy in animal models of osteoporosis, with potential indications for an improved safety profile. Clinical efficacy data from ongoing phase III trials are awaited so that a true understanding of the therapeutic potential of these compounds can be obtained.
Similar articles
-
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.Curr Clin Pharmacol. 2013 May;8(2):135-55. doi: 10.2174/1574884711308020006. Curr Clin Pharmacol. 2013. PMID: 23062036 Free PMC article. Review.
-
Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.Drugs Today (Barc). 2006 Jun;42(6):355-67. doi: 10.1358/dot.2006.42.6.973583. Drugs Today (Barc). 2006. PMID: 16845439 Review.
-
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.Menopause. 2010 May-Jun;17(3):642-53. doi: 10.1097/gme.0b013e3181c4f1d6. Menopause. 2010. PMID: 20107426 Review.
-
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].Clin Calcium. 2004 Oct;14(10):85-93. Clin Calcium. 2004. PMID: 15577137 Review. Japanese.
-
Selective estrogen receptor modulators in clinical practice: a safety overview.Expert Opin Drug Saf. 2015 Jun;14(6):921-34. doi: 10.1517/14740338.2015.1014799. Epub 2015 May 2. Expert Opin Drug Saf. 2015. PMID: 25936229 Review.
Cited by
-
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.Br J Cancer. 2010 Jan 19;102(2):294-300. doi: 10.1038/sj.bjc.6605460. Epub 2009 Dec 1. Br J Cancer. 2010. PMID: 19953095 Free PMC article. Clinical Trial.
-
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Int J Womens Health. 2010 Aug 9;1:11-20. doi: 10.2147/ijwh.s3894. Int J Womens Health. 2010. PMID: 21072271 Free PMC article.
-
Bazedoxifene: a guide to its use in postmenopausal osteoporosis.Drugs Aging. 2012 Apr 1;29(4):329-34. doi: 10.2165/11207810-000000000-00000. Drugs Aging. 2012. PMID: 22462631
-
CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: 10.1016/j.bbrc.2013.10.057. Epub 2013 Oct 19. Biochem Biophys Res Commun. 2013. PMID: 24148245 Free PMC article.
-
Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice.Endocrinology. 2008 May;149(5):2607-11. doi: 10.1210/en.2007-1346. Epub 2008 Feb 14. Endocrinology. 2008. PMID: 18276750 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous